Point-of-Care Ultrasound Is the Quiet Revolution in Diagnostics
Dr. Dereck Mush, MD, MBA
VertigoDx
Smartphone-based point-of-care vestibular testing with AI-guided nystagmus classification.
What they do
VertigoDx makes SmartVertigo, a prescription vestibular assessment system that pairs a smartphone, a light-occluding headset and software to capture horizontal, vertical and torsional nystagmus during standard positional tests such as Dix-Hallpike. The system received FDA 510(k) clearance (K260566) on July 30, 2026, announced September 29, 2026. It was developed with Florida Atlantic University. Leadership includes co-founder and CEO Dr. Paul Louis and co-founder Trevor Meyerowitz.
The record
- Vertical
- Medical Devices
- Sub-segment
- Vestibular diagnostics
- Product type
- Medical device
- Stage
- Private
- Headquarters
- Wilmington, DE and Miami, FL, USA
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Medical Devices
Related on The Signal
Dr. Dereck Mush, MD, MBA
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
The 8 Best AI Diagnostic Tools of 2026
AI diagnostics stopped being experimental. These eight tools are FDA-cleared, deployed at scale, and quietly changing how disease gets found.
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
The 8 Most Innovative MedTech Devices Right Now
From a pacemaker the size of a vitamin to a scanner that books its own follow-up, these are the devices actually changing care in 2026.
Dr. Dereck Mush, MD, MBA